Christopher L. Wight

ChrisChristopher L. Wight – Registered Patent Attorney

Chris specializes in protecting intellectual property in chemical, pharmaceutical, biotechnology and medical device technologies.  His experience includes U.S. and international patent preparation and prosecution, legal opinions and technology licensing. He has successfully obtained hundreds of U.S. and foreign patents for his clients in a diverse range of life science and chemical technologies.

With extensive experience in both law firm and in-house environments for over 28 years, Chris understands the diverse legal needs and business demands of his clients, and is highly effective at identifying and protecting IP in a complex and competitive marketplace. Chris has served in senior leadership roles with two highly successful publicly-traded life science companies – Myriad Genetics and Immunex Corporation.  As Director of Intellectual Property at Immunex Corporation (acquired by Amgen in 2002), he was responsible for developing and implementing Immunex’s corporate intellectual property strategy, including direct responsibility for the patent portfolio covering various biopharmaceutical products, including LEUKINE and ENBREL, now one of the world’s highest grossing biologic drugs, with current world-wide annual revenues of nearly $7 billion. Immunex’s ENBREL product (and the strength of its patent portfolio) was the principal economic driving force behind Amgen’s $16 billion acquisition of Immunex in 2002. Chris subsequently served as Vice President & General Counsel of Myriad Genetics, widely considered the preeminent genetic testing company in the world, where he was responsible for directing the development of intellectual property relating to Myriad’s genetic testing business, including Myriad’s patents covering its BRACANALYSIS breast cancer predisposition test. Chris was also formerly affiliated with two highly respected law firms – Brinks Hofer Gilson & Lione and Holland & Hart – where he served as outside counsel to numerous chemical, biopharmaceutical, molecular diagnostic, and medical device companies in a diverse range of technologies.

Chris has a unique perspective and set of skills that enable him to effectively and efficiently identify and protect intellectual property assets. He is able to apply complex principles of intellectual property law to diverse technologies, effectively communicate with both Ph.D.-level scientific personnel and corporate executives, and provide quality service at competitive rates. He understands the needs and expectations of clients who demand competent and cost-effective representation on intellectual property matters, and can effectively anticipate, manage and reduce legal costs.

Contact Christopher


Chris’s practice focuses on providing intellectual property legal services and strategic counseling for the life science and chemical industries, specifically in the chemical, pharmaceutical, biotechnology, medical diagnostic/personalized medicine and medical device fields, including the following:

  • Preparing and prosecuting U.S. and international patent applications
  • Patent strategy and product life cycle planning
  • Performing evaluations, audits, due diligence reviews and opinions of intellectual property in patent, trade secret and licensing matters, including opinions relating to
    • Patentability
    • Invalidity
    • Non-infringement/product clearance
  • Negotiating and drafting technology development and transfer agreements, including
    • Licensing agreements
    • R&D collaboration agreements
    • Manufacturing agreements
    • Non-disclosure/confidentiality agreements
    • Supply and distribution agreements
  • Providing product design-around analysis and counseling
  • Outsourcing general counsel and IP attorney services for start-up and emerging technology companies
    • Employee training to develop IP awareness
    • Monitoring early development of technology to identify and protect valuable IP
    • Establishing corporate legal and IP policies
    • Developing corporate IP functions (hiring/training personnel, administration/maintenance of IP, etc.)

Professional Admissions

  • Utah State Bar
  • Illinois State Bar
  • United States Patent and Trademark Office


  • Presentation, Gene Patents: The Supreme Courts Decision in AMP V. Myriad Genetics, Bid Utah Wasters Series, December 2013
  • Presentation, The Future of Gene Patents, Patenting DNA and other Biomolecules, Bid Utah Summit, November 2013
  • Publication, Patent Protection in China, Utah CEO Magazine, July 2010
  • Presentation, Patentability of DNA: The Clash Between Patent Policies and Personalized Medicine in ACLU v. Myriad Genetics, Utah Technology Council Life Science Seminar, May 2010
  • Presentation, Patent Eligibility for Nanotech and Biotech Inventions, Nanotechnology Conference, Chicago Illinois, November 2009
  • Publication, Recruiting and Retaining a Highly Skilled Workforce in a Flattening World Economy,Connect, April 2008
  • Presentation, Prosecution Under the New Continuation Rules, University of Utah Technology Commercialization Office, September 2006
  • Presentation, Patenting Biotechnology, ARUP Laboratories, October 2006
  • Presentation, Patentability Issues in Biotechnology Cases, Biotech Bootcamp, Denver, Colorado, 2004
  • Presentation, A New Era of Patent Legal Opinions, BioWest Conference, October 2004
  • Presentation, How to Negotiate Confidentiality Agreements, Utah Innovation Conference, May 2004
  • Presentation, Intellectual Property Ownership Problems in Strategic Alliances: Allocating Rights to New Developments, Licensing Executive Society, June 2003
  • Publication, Interference with Business and Economic Interests, B.Y.U. JOURNAL OF LEGAL STUDIES, 1984


  • J.D., J. Reuben Clark Law School, Brigham Young University, 1985
    Managing Editor, Brigham Young University Journal of Legal Studies, 1984-1985
  • B.A., Chemistry, Brigham Young University, 1982


  • Voted “Utah’s Legal Elite” by Utah Business Magazine, 2008, 2009, 2010


  • Chemistry/biochemistry
  • Molecular biology
  • Genetics
  • Pharmaceuticals
  • Nucleic acid diagnostics, biomarkers
  • Nucleic acid analogs
  • DNA Sequencing
  • Gene therapy
  • Antibodies
  • Immunology
  • Vaccines/adjuvants
  • Protein chemistry
  • Cell culture
  • Formulation chemistry
  • Drug delivery systems
  • Materials chemistry
  • Metallurgy
  • Nanotechnology
  • Medical treatments
  • Microfluidics
  • Manufacturing/chemical processes
  • Medical devices